Literature DB >> 19851344

The CVD paradox: mortality vs prevalence.

Valentin Fuster, Bryony M Mearns.   

Abstract

Mesh：

Year:  2009        PMID： 19851344     DOI： 10.1038/nrcardio.2009.187

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  3 in total

1.  Global public health: a scorecard.

Authors:  Robert Beaglehole; Ruth Bonita
Journal:  Lancet       Date:  2008-10-20       Impact factor: 79.321

2.  How much of the recent decline in the incidence of myocardial infarction in British men can be explained by changes in cardiovascular risk factors? Evidence from a prospective population-based study.

Authors:  Sarah L Hardoon; Peter H Whincup; Lucy T Lennon; S Goya Wannamethee; Simon Capewell; Richard W Morris
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

3.  Contribution of changes in incidence and mortality to trends in the prevalence of coronary heart disease in the UK: 1996 2005.

Authors:  Alisha Ruth Davies; Liam Smeeth; Emily Marjatta Dorothea Grundy
Journal:  Eur Heart J       Date:  2007-07-18       Impact factor: 29.983
  3 in total
  14 in total

1.  The SHAPE guideline: ahead of its time or just in time?

Authors:  Erling Falk; Prediman K Shah
Journal:  Curr Atheroscler Rep       Date:  2011-10       Impact factor: 5.113

Review 2.  Early identification of atherosclerotic disease by noninvasive imaging.

Authors:  Valentin Fuster; Fátima Lois; Manuel Franco
Journal:  Nat Rev Cardiol       Date:  2010-05-04       Impact factor: 32.419

3.  [ESC/EACTS guidelines on myocardial revascularization : Amendments 2014].

Authors:  H Nef; M Renker; C W Hamm
Journal:  Herz       Date:  2014-12       Impact factor: 1.443

4.  Lack of an association between connexin-37, stromelysin-1, plasminogen activator-inhibitor type 1 and lymphotoxin-alpha genes and acute coronary syndrome in Czech Caucasians.

Authors:  Jaroslav Alois Hubacek; Vladimír Staněk; Marie Gebauerová; Alexandra Pilipčincová; Rudolf Poledne; Michal Aschermann; Hana Skalická; Jana Matoušková; Andreas Kruger; Martin Pěnička; Hana Hrabáková; Josef Veselka; Petr Hájek; Vera Lánská; Věra Adámková; Jan Pit'ha
Journal:  Exp Clin Cardiol       Date:  2010

5.  Myocardial fibrosis by T1 mapping magnetic resonance imaging predicts incident cardiovascular events and all-cause mortality: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Mateus D Marques; Raquel Weinberg; Shrey Kapoor; Mohammad R Ostovaneh; Yoko Kato; Chia Ying Liu; Steven Shea; Robyn L McClelland; Wendy S Post; David A Bluemke; João A C Lima; Bharath Ambale-Venkatesh
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2022-09-10       Impact factor: 9.130

Review 6.  Imaging of coronary atherosclerosis in various susceptible groups.

Authors:  Ravi Kiran Munnur; Nitesh Nerlekar; Dennis T L Wong
Journal:  Cardiovasc Diagn Ther       Date:  2016-08

7.  The high-risk plaque initiative: primary prevention of atherothrombotic events in the asymptomatic population.

Authors:  Erling Falk; Henrik Sillesen; Pieter Muntendam; Valentin Fuster
Journal:  Curr Atheroscler Rep       Date:  2011-10       Impact factor: 5.113

8.  Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study.

Authors:  Maarten J G Leening; Maryam Kavousi; Jan Heeringa; Frank J A van Rooij; Jolande Verkroost-van Heemst; Jaap W Deckers; Francesco U S Mattace-Raso; Gijsbertus Ziere; Albert Hofman; Bruno H Ch Stricker; Jacqueline C M Witteman
Journal:  Eur J Epidemiol       Date:  2012-03-03       Impact factor: 8.082

9.  Peony seed oil decreases plasma cholesterol and favorably modulates gut microbiota in hypercholesterolemic hamsters.

Authors:  Erika Kwek; Hanyue Zhu; Huafang Ding; Zouyan He; Wangjun Hao; Jianhui Liu; Ka Ying Ma; Zhen-Yu Chen
Journal:  Eur J Nutr       Date:  2022-02-02       Impact factor: 4.865

10.  Atherosclerosis: from biology to pharmacological treatment.

Authors:  Graziano Riccioni; Valeriana Sblendorio
Journal:  J Geriatr Cardiol       Date:  2012-09       Impact factor: 3.327
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.